Immunotherapy in Advanced Urothelial Cancer- Matthew Campbell

Matthew Campbell, MD, provides an overview of metastatic urothelial cancer (mUC) and PD-1/PD-L1 blockade as the new standard in second line therapy.  In addition, Dr. Campbell discuss the ongoing and future exploration in UC.

Matthew Campbell Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Additional reading:
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

A phase II study of atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients 

Systemic Immunotherapy Bladder Cancer.. Get Ready